Show simple item record

dc.contributor.authorReimer, Michele E.en_US
dc.date.accessioned2014-03-14T20:37:47Z
dc.date.available2014-03-14T20:37:47Z
dc.date.issued1999-02-24en_US
dc.identifier.otheretd-052099-150259en_US
dc.identifier.urihttp://hdl.handle.net/10919/33049
dc.description.abstractTwenty-four healthy, mixed breed dogs were divided into four groups. Group I received a placebo PO BID, group II received an average 16.5 (range, 15.1-17.8) mg/kg buffered aspirin PO BID, group III received an average 2.2 (range, 2.0-2.4) mg/kg carprofen PO BID, and group IV received an average 12.8 (range, 11.7-13.8) mg/kg etodolac PO QD (with a placebo in the P.M.). All treatments continued for 28 consecutive days. Gastroduodenal endoscopy was performed on days â 9, 0, 5, 14 and 28. Multiple gastric biopsies were obtained endoscopically on day â 9 to determine each dogâ s Helicobacter spp. status.

Five areas, consisting of four regions in the stomach and one in the proximal duodenum, were evaluated endoscopically, and each was assigned a score from 1 to 11 based on qualitative assessment of submucosal hemorrhage, erosion, or ulceration. These scores for each region were then summed to give a total score for each endoscopic evaluation.

Erosions and submucosal hemorrhages were seen in all dogs receiving aspirin. Only minor gastric lesions were observed in the carprofen, etodolac, and control groups. No adverse clinical signs were noted in any dog given any treatment during the course of the study. There was no predilection site for lesion development in any group. Median total score on days 0, 5, 14, and 28 were as follows: group I, 5.0, 5.0, 5.0, 5.0; group II, 5.0, 27.0, 26.0, 27.5; group III, 5.0, 5.0, 6.0, 5.0; group IV, 5.0, 7.0, 5.0, 5.0, respectively.

There was no significant difference between dogs receiving carprofen, etodolac, or placebo. The administration of carprofen, etodolac, or placebo to healthy dogs resulted in significantly less gastroduodenal lesion development than in dogs receiving buffered aspirin.

en_US
dc.publisherVirginia Techen_US
dc.relation.haspartMer_etd.pdfen_US
dc.rightsI hereby grant to Virginia Tech or its agents the right to archive and to make available my thesis or dissertation in whole or in part in the University Libraries in all forms of media, now or hereafter known. I retain all proprietary rights, such as patent rights. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation.en_US
dc.subjectNon-steroidal Anti-inflammatory drugsen_US
dc.subjectEndoscopyen_US
dc.subjectGastric Ulcerationen_US
dc.subjectCarprofenen_US
dc.subjectHelicobacteren_US
dc.subjectCanineen_US
dc.subjectEtodolacen_US
dc.titleTHE GASTRODUODENAL EFFECTS OF BUFFERED ASPIRIN, CARPROFEN, AND ETODOLAC IN THE HEALTHY DOG and COMPARISON OF THE CLOTEST® TO HISTOPATHOLOGIC EVALUATION IN IDENTIFYING THE PRESENCE OF HELICOBACTER SPP. IN HEALTHY DOGSen_US
dc.typeThesisen_US
dc.contributor.departmentVeterinary Medical Sciencesen_US
dc.description.degreeMaster of Scienceen_US
thesis.degree.nameMaster of Scienceen_US
thesis.degree.levelmastersen_US
thesis.degree.grantorVirginia Polytechnic Institute and State Universityen_US
thesis.degree.disciplineVeterinary Medical Sciencesen_US
dc.contributor.committeechairJohnston, Spencer A.en_US
dc.contributor.committeememberPfeiffer, Carl J.en_US
dc.contributor.committeememberLeib, Michael S.en_US
dc.contributor.committeememberDuncan, Robert B. Jr.en_US
dc.identifier.sourceurlhttp://scholar.lib.vt.edu/theses/available/etd-052099-150259/en_US
dc.date.sdate1999-05-20en_US
dc.date.rdate2012-04-12
dc.date.adate1999-05-22en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record